The Effects of GLP-1 on Glucose Metabolism: A Comprehensive Review
Glucagon-like peptide-1 (GLP-1) has emerged as a powerful player in regulating metabolism and a promising therapeutic target for various chronic diseases. This review delves into the physiological roles of GLP-1, exploring its impact on glucose homeostasis, insulin secretion, and satiety. We examine the compelling evidence supporting GLP-1 receptor agonists (GLP-1RAs) in managing type 2 diabetes and obesity.Physiological Roles of GLP-1
GLP-1 is a peptide hormone released from the intestinal tract in response to food intake. It plays a central role in coordinating postprandial glucose homeostasis through actions on insulin secretion, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-2 (GLP-2). GLP-1 has been shown to have a strong blood glucose-lowering effect through pharmacological actions, such as gastric emptying and appetite suppression, in addition to promoting insulin secretion and inhibiting glucagon secretion.Impact on Glucose Metabolism
GLP-1 has been demonstrated to have a significant impact on glucose metabolism, including:- Stimulating insulin secretion from pancreatic beta cells
- Suppressing glucagon secretion from pancreatic alpha cells
- Regulating glucose-dependent insulinotropic polypeptide (GIP) secretion
- Slowing gastric emptying and reducing appetite
- Improving insulin sensitivity and glucose uptake in skeletal muscle
GLP-1 Receptor Agonists (GLP-1RAs)
GLP-1RAs have become a cornerstone in the management of type 2 diabetes and obesity. These drugs work by activating the GLP-1 receptor, which is found on pancreatic beta cells, neurons in the brain, and other tissues. GLP-1RAs have been shown to have a range of benefits, including:- Improving glycemic control
- Reducing body weight
- Lowering blood pressure
- Improving lipid profiles
- Reducing cardiovascular risk
